Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90

被引:1
|
作者
Chen Tian-wen [1 ]
Liang Ya-nan [1 ]
Feng Duo [1 ]
Tao Lin-yu [1 ]
Qi Ke [1 ]
Zhang Hao-yun [1 ]
Wang Hong-xian [1 ]
Lin Qiu-sheng [1 ]
Kong Heng [1 ]
机构
[1] Guangdong Med Coll, Affiliated Nanshan Hosp, Dept Thyroid & Breast Surg, Shenzhen 518052, Peoples R China
来源
JOURNAL OF BUON | 2013年 / 18卷 / 01期
关键词
breast cancer; heat-shock protein90; HER2/neu; metformin; CHEMOTHERAPY; TRASTUZUMAB;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the effects and the possible molecular mechanisms of metformin on HER2 positive breast cancer cells. Methods: SK-BR-3 HER2 positive breast cancer cells were treated with different concentrations of metformin. The growth inhibitory rate of the cells was calculated by MTT assay, apoptosis was detected by flow cytometry, and the expression level of heat shock protein 90 (HSP90) was performed by Western blot analysis. A control group consisted of cells treated with PBS. Results: With increased concentrations of metformin, cell growth inhibitory rates increased. The growth inhibitory rates with 0.5 mM, 2mM or 8mM metformin were significantly higher compared with the control group (p<0.05). Apoptosis in the metformin treated cells was also significantly higher compared with the control group (p=0.003). The expression level of HSP90 in the metformin group was significantly lower than that in the control group. Conclusion: Metformin can inhibit the proliferation and promote apoptosis of HER2 positive breast cancer cells,which is maybe related to inhibition of HSP90.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 50 条
  • [31] BJ-B11, an Hsp90 Inhibitor, Constrains the Proliferation and Invasion of Breast Cancer Cells
    Liu, Kaisheng
    Chen, Juan
    Yang, Fang
    Zhou, Zhifan
    Liu, Ying
    Guo, Yaomin
    Hu, Hong
    Gao, Hengyuan
    Li, Haili
    Zhou, Wenbin
    Qin, Bo
    Wang, Yifei
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [32] α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling
    Zhuo, Ren-Jie
    Wang, Feng
    Zhang, Xiao-Hong
    Zhang, Jin-Jie
    Xu, Jin
    Dong, Wei
    Zou, Zu-Quan
    MOLECULAR MEDICINE REPORTS, 2014, 9 (03) : 993 - 998
  • [33] Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C
    Fang, Fuxiao
    Yuan, Qing
    ONCOLOGY LETTERS, 2022, 23 (02)
  • [34] Evaluating Trastuzumab in the treatment of HER2 positive breast cancer
    Jaques, Ryan
    Xu, Sam
    Matsakas, Antonios
    HISTOLOGY AND HISTOPATHOLOGY, 2020, 35 (10) : 1059 - 1075
  • [35] Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
    Mou, Exian
    Ji, Juan
    Liu, Shiwei
    Shu, Lan
    Zou, Liqun
    Li, Zhuoxuan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [36] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04) : 535 - 540
  • [37] Immune Effects of Transtuzumab in HER2 Positive Breast Cancer
    Zgura, Anca
    Gales, Laurentia
    Haineala, Bogdan
    Bratila, Elvira
    Mehedintu, Claudia
    Barac, Ramona Ileana
    Berceanu, Costin
    Andreescu, Cristina Veronica
    Brinduse, Lacramioara Aurelia
    Ionescu, Alec
    Anghel, Rodica
    REVISTA DE CHIMIE, 2019, 70 (08): : 2791 - 2794
  • [38] HSP90 inhibits apoptosis and promotes growth by regulating HIF-1α abundance in hepatocellular carcinoma
    Liu, Xin
    Chen, Shuda
    Tu, Jianfeng
    Cai, Wenwei
    Xu, Qiuran
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 37 (03) : 825 - 835
  • [39] Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells
    Kaczynska, Angelika
    Herman-Antosiewicz, Anna
    BREAST CANCER, 2017, 24 (02) : 271 - 280
  • [40] Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing
    Pathmanathan, Nirmala
    Provan, Pamela J.
    Mahajan, Hema
    Hall, Geoffrey
    Byth, Karen
    Bilous, A. Michael
    Balleine, Rosemary L.
    BREAST, 2012, 21 (06) : 724 - 729